Sharon W. W. Chan

Suggest Changes
Learn More
BACKGROUND The Oncotype DX Breast Cancer Assay is validated to assess risk of distant recurrence and likelihood of chemotherapy (CT) benefit in estrogen receptor-positive ESBC in various populations.(More)